No association between cortical dopamine D2 receptor availability and cognition in antipsychotic-naive first-episode psychosis

Maria Lee1,2✉, Helena Fatouros-Bergman3, Pontus Pläven-Sigray1,2, Pauliina Ikonen Victorsson1, Carl M. Sellgren1, Sophie Erhardt3, Lena Flyckt1, Lars Farde1 and Simon Cervenka1,4

Cognitive impairment is an important predictor of disability in schizophrenia. Dopamine neurotransmission in cortical brain regions has been suggested to be of importance for higher-order cognitive processes. The aim of this study was to examine the relationship between extrastriatal dopamine D2-R availability and cognitive function, using positron emission tomography and the high-affinity D2-R radioligand [11C]FLB 457, in an antipsychotic-naive sample of 18 first-episode psychosis patients and 16 control subjects. We observed no significant associations between D2-R binding in the dorsolateral prefrontal cortex or hippocampus (β = 0.013–0.074, partial r = −0.037–0.273, p = 0.131–0.841). Instead, using Bayesian statistics, we found moderate support for the null hypothesis of no relationship (BFH0:H1 = 3.3–8.2). Theoretically, our findings may suggest a lack of detrimental effects of D2-R antagonist drugs on cognition in schizophrenia patients, in line with clinical observations.

INTRODUCTION

Diagnostic criteria for schizophrenia include positive symptoms (delusions, hallucinations, disorganized speech, and behavior) and negative symptoms (loss of motivation, blunted affect, etc.). Beyond these symptoms, a majority of patients also have a cognitive impairment, with global functioning significantly below that of healthy controls (HCs).1 The cognitive domains that are most severely affected include verbal learning and memory, processing speed, working memory, and executive function, and the level of dysfunction seems to be similar in medicated2–4 and antipsychotic drug-naive patients5. In addition, it has been hypothesized that the pathology underlying cognitive impairment also contributes to positive symptoms6 and cognitive status has been shown to predict functional outcomes better than any other symptom dimension7,8.

Molecular imaging studies using positron emission tomography (PET) and single-photon emission computed tomographic (SPECT) have provided evidence of the abnormal function of the dopamine system in schizophrenia; primarily in the form of elevations in presynaptic dopamine synthesis capacity and amphetamine-induced dopamine release in striatal regions9. With regard to receptor subtypes, pharmacological and genetic evidence provides indirect support for an involvement of the dopamine D2 receptor (D2-R) in the pathophysiology of schizophrenia9–11. PET studies have shown a slight increase of this receptor subtype in schizophrenia in striatum11, and in parallel striatal D2-R has in several studies been reported to be associated with measures of processing speed and executive function in healthy subjects12–14 as well as in drug-free patients with schizophrenia15.

A wealth of literature has established that the frontal cortex and hippocampus are key regions for higher-order cognition in humans. In patients with schizophrenia, altered activation in these regions has been linked to cognitive performance, using functional resonance imaging16–18. Given the role of D2-R in cognition, surprisingly few studies have investigated the relationship between D2-R availability and cognition in extrastriatal regions. Four studies have so far investigated this relationship in patients with schizophrenia revealing no clear pattern of associations19–22. Moreover, the observed correlations in these studies differ from those observed in HC; either showing associations in the opposite direction or a lack of a significant relationship23–26 (see Supplementary Table 1).

The purpose of this study was to examine the relationship between D2 receptor availability and cognitive function in an antipsychotic drug-naive sample of first-episode psychosis (FEP) patients and HC subjects. Based on the existing literature, we selected specific cognitive domains and brain regions a priori to preserve sufficient statistical power, and we utilized both frequentist and Bayesian statistics to gain more information about potential associations.

RESULTS

Data on demographics are presented in Table 1. FEP and HC did not differ significantly in terms of age, gender, body mass index, nicotine use, or years of education.

The regions of interest (ROI) for the confirmatory analyses were the dorsolateral prefrontal cortex (DLPFC) with a mean [11C]FLB 457 binding potential (BPND) of 0.80 (SD 0.23) for patients and 0.83 (SD 0.32) for controls; as well as the hippocampus with a mean BPND of 1.27 (SD 0.24) for patients and 1.17 (SD 0.20) for controls. In Table 2, the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) cognitive tests and domains, used in the confirmatory analyses are presented. The values listed are raw
The main effect of cognition on BPND was not found to be statistically significant for any of the tests and regions investigated ($\beta = 0.013 \pm 0.074$, $p = 0.131 \pm 0.841$, partial $r = -0.037 \pm 0.273$) (Fig. 1). None of the interaction effects were statistically significant. BF in favor of $H_0$ relative to $H_1$ were all above 3 ($BF_{H0:H1} 3.3 \pm 8.2$, see Table 3), indicating moderate evidence in favor of the null hypothesis of no relationship between cognitive function and D2-R availability. The main confirmatory analyses were re-run without the three FEP individuals with a diagnosis of delusional disorder (Supplementary Tables 3, 4), yielding similar results.

Gender effects on cognition have been observed in the general population using the MCCB, as well as in samples of patients with schizophrenia. We did not set out to test the potential impact of gender in this study, given our small sample size. Post hoc, we added gender as a covariate to our model, but this did not change the results (see Supplementary Table 5).

### Exploratory analyses

For descriptive statistics on the exploratory cognitive domains, see Supplementary Table 2. In the analyses of the main effect of cognition, attention was positively correlated with D2-R availability in several ROIs (hippocampus: $r = 0.521$, temporal cortex (TC): $r = 0.474$, anterior cingulate cortex (ACC): $r = 0.326$, thalamus: $r = 0.300$). All other associations between regional BPND and cognitive domains showed small partial correlation values, below 0.3 (see Supplementary Table 6). When including the effect of FEP/HC status, an interaction effect was observed for the relationship between visual learning and BPND in the hippocampus. After examining the partial correlations for the groups separately, this relationship was driven by the HC who showed a medium-sized positive correlation ($r = 0.613$), whereas FEP shows a negligible negative correlation ($r = -0.184$) (Supplementary Tables 7, 8).

### Longitudinal analyses

Partial correlations between [11C]FLB 457 BPND and cognition at 1.5-year follow-up were explored. Associations of a moderate magnitude (partial $r = 0.5$) were found for the relationship between D2-R availability in the hippocampus and the cognitive domain attention (see Supplementary Table 9). Exploratory analyses between the baseline BPND levels and change in cognitive test results from baseline to follow-up were also performed, see Supplementary Table 10.

### DISCUSSION

In this study, we investigated the relationship between regional dopamine D2 receptor binding and cognition in a well-defined cohort of drug-naive FEP and matched HC. We used high-resolution PET, a radioligand with very high affinity, well suited to quantify D2-R availability in low-density extrastriatal brain regions, and a battery of cognitive tests specifically developed...
to be sensitive to cognitive impairment in schizophrenia. Contrary to our hypotheses, no significant associations between D2-R availability in pre-defined regions and cognitive function were observed. Instead, we obtained moderate support in favor of the null hypothesis of no relationship between D2-R and cognition, relative to the alternative hypothesis. This suggests a lack of a sizeable, and thereby clinically relevant, the relationship between D2-R availability in the frontal cortex and the hippocampus and working memory, speed of processing, or verbal learning in FEP and HC.

This study was not designed to test the effects of antipsychotic drugs on cognition. However, the absence of an association between extrastriatal D2-R availability and cognition may be viewed in light of the fact that all currently available antipsychotic drugs act by occupying this receptor subtype. Whereas experimental studies in HC have demonstrated a negative effect on cognition by antipsychotic drugs32, clinical studies on patients with psychotic disorders have produced more mixed results33. Although some studies report negative effects34–36 others report positive37,38 or no effect on cognition39. Moreover, meta-analyses of cognitive function in drug-naïve FEP show the same level of impairment as in patients who have been treated with D2-R blocking drugs40,41. Theoretically, the lack of relationship between D2-R and cognition in the present study is in line with the view that D2-R blocking drugs may not worsen cognitive function in patients with schizophrenia.

Previous studies have reported associations between D2-R availability and cognition that differ between patients with schizophrenia and HC. In some cases, significant correlations have been reported in one group but not the other42,43, and in other cases, the direction of the relationship has been reversed between groups44,45. The idea of an altered impact of dopamine on cognitive function in schizophrenia motivated us to explore an interaction effect of FEP/HC status on the relationship between cognitive functioning and D2-R availability. However, we found no support in our data for this hypothesis.

In the exploratory analysis, a sizeable positive correlation was observed between attention and D2-R in the hippocampus, TC, Table 3.

|           | β (95% CI)   | Partial r | Df | p value | BF <H0:1> |
|-----------|--------------|-----------|----|---------|-----------|
| Verbal learning and D2-R in DLPFC | 0.074 (-0.023–0.171) | 0.273 | 30 | 0.131 | 3.3 |
| Verbal learning and D2-R in hippocampus | 0.031 (-0.069–0.132) | 0.115 | 30 | 0.529 | 8.2 |
| Working memory and D2-R in DLPFC | -0.039 (-0.123–0.044) | -0.174 | 30 | 0.341 | 7.6 |
| Speed of processing and D2-R in DLPFC | -0.013 (-0.140–0.115) | -0.037 | 30 | 0.841 | 7.7 |

Table 4. Confirmatory analyses with an added interaction effect.

|           | β (95% CI) interaction effect | Df | p value | Partial r FEP | Df | p value FEP | Partial r HC | Df | p value HC |
|-----------|-----------------------------|----|---------|---------------|----|-------------|--------------|----|-----------|
| Verbal learning D2-R DLPFC | -0.143 (-0.352–0.066) | 29 | 0.173 | 0.134 | 15 | 0.608 | 0.443 | 13 | 0.098 |
| Verbal learning D2-R hippocampus | -0.137 (-0.354–0.080) | 29 | 0.207 | -0.034 | 15 | 0.896 | -0.419 | 13 | 0.120 |
| Working memory D2-R DLPFC | 0.134 (-0.039–0.306) | 29 | 0.124 | 0.060 | 15 | 0.819 | -0.402 | 13 | 0.138 |
| Speed of processing D2-R DLPFC | 0.097 (-0.203–0.397) | 29 | 0.513 | 0.020 | 15 | 0.938 | -0.114 | 13 | 0.685 |

Fig. 1 Relationship between [11C]FLB 457 BPND values and age-corrected cognitive test scores for the confirmatory analyses. Blue circles indicate HC, red triangles indicate FEP. The gray area indicates a 95% confidence interval for the regression line. a BPND in DLPFC and verbal learning, b BPND in the hippocampus and verbal learning, c BPND in DLPFC and working memory, d BPND in DLPFC and speed of processing.
ACC, and thalamus. Attention has been considered to be the foundation for other higher-order cognitive abilities known to be impaired in schizophrenia, as well as related to positive symptoms of the disease. Moreover, the prefrontal cortex and the ACC have been associated with measures of attention in the previous lesion and imaging studies. This potential association warrants further investigation in other independent samples of patients with schizophrenia and controls.

The existing literature on the association between D2 receptor availability and cognitive performance in patients with schizophrenia has produced mixed results (see Supplementary Table 1). Sifftstein et al. found no relationship between working memory and basal D2-R availability (BPND) in the DLPCF as determined using [11C]FLB 457 PET. Using the same radioligand, Rao et al. tentatively observed a negative correlation between D2-R availability in the DLPCF and language/medium of processing measures in an exploratory analysis. Another study observed a positive linear correlation between D2-R binding in the frontal cortex and set-shifting in antipsychotic-naive FEP, using the SPECT radiotracer [123I]Iepipidepride. Moreover, quadratic correlations between D2-R and planning efficiency, planning latency, and selective attention were observed. Finally, [18F]fallypride has been used to demonstrate negative correlations between D2-R in several brain regions and verbal learning as well as executive function in patients with schizophrenia. In summary, previous imaging studies have utilized different techniques and radioligands, while investigating varying cortical regions and cognitive outcome measures, limiting the conclusions that can be drawn. Moreover, in these studies, it may be argued that there was an insufficient correction for multiple comparisons. We sought to improve on this in the present study by defining our analyses a priori and correcting for multiple comparisons. An additional strength is that we utilized Bayesian methods to gain more information from a nonsignificant result by quantifying the relative support for the null hypothesis against a skeptical but plausible alternative hypothesis.

As with previous studies in the field, the major limitation of our study was the sample size. The study was powered to detect a medium effect size, and in order to detect more subtle associations, larger samples are needed. Notably, we were not able to demonstrate significant differences in performance between FEP and HC on several cognitive measures previously shown to be impaired in patients (working memory, verbal learning, and executive function). PET examination and cognitive testing were performed at different times, and two FEP were no longer drug-naive at the time of cognitive testing. Cognitive testing of patients in the initial phase of their first psychotic episode introduces potential bias; psychotic symptoms, sleep deprivation, and/or stress likely introduce some noise in our cognitive outcome measures. This weakness has to be weighed against the advantages of obtaining [11C]FLB 457 PET values at the first onset of the disease, before exposure to the confounding effects of antipsychotic medication. A related concern is a potential for selection bias with our study design. Recruiting drug-naive FEP patients who are able to consent and take part in a PET study is challenging and might result in patients who have milder symptoms (able to post-pone drug treatment) and are more positively inclined towards research in general (potentially related to educational level). The fact that substance use was an exclusion criterion also limits the generalizability of our findings to the general population of patients with schizophrenia. Given these inherent challenges, we still conclude that our sample is not atypical compared with other molecular imaging studies using drug-naive or drug-free FEP in terms of age, duration of untreated psychosis, or symptom burden.

Our main finding is moderate support for no relationship between D2-R and cognition in a sample of FEP, as quantified using Bayes Factor. This is in line with clinical data suggesting a lack of significant negative effects of antipsychotic drugs on cognitive function in patients with schizophrenia. More work is needed to understand how aberrations in dopamine function may impact different symptom domains in schizophrenia, preferably using larger samples and collaborations between imaging centers to gain more conclusive evidence.

METHODS

Participants

The study was approved by the Regional Ethics Committee in Stockholm (diary number: 2010/879-31-1) as well as the Radiation Safety Committee of the Karolinska University Hospital. Subjects were included after providing written informed consent.

Twenty antipsychotic-naive, FEP patients were included from three psychiatric clinics in Stockholm, as part of the Karolinska Schizophrenia Project (KaSP). One participant was later excluded owing to brain abnormalities demonstrated by magnetic resonance imaging (MRI) and age (65 years at scan) and one participant was excluded due to missing MRI, making the final number of FEP 18 (11 male, seven female, mean age 28.9 years (SD 6.3)). At the time of PET investigation, all FEP were naive to antipsychotic treatment and met the diagnostic criteria for schizophrenia (N = 6), schizophreniaform disorder (N = 5), psychotic disorder NOS (N = 4), or delusional disorder (N = 3) according to DSM-IV. Exclusion criteria were neurologic or severe somatic illness and current use or history of abuse of illegal drugs (including cannabis). The Alcohol Use Disorders Identification Test (AUDIT) and Drug Use Disorders Identification Test (DUDIT) were used to assess the use of illegal drugs and alcohol abuse, along with a urine drug screen test prior to the PET scan.

Sixteen HC subjects (10 male, 6 female, mean age 29.3 years (SD 6.2)) were recruited by advertisement. Subjects were healthy according to medical history, clinical examination, routine laboratory blood test as well as a brain MRI examination. The Mini-International Neuropsychiatric Interview (MINI) was used to exclude previous or current psychiatric illness. Further exclusion criteria were previous or current use of illegal drugs (assessed using AUDIT and DUDIT, and urine toxicology prior to PET) and first-degree relatives with psychotic illness. See Table 1 for demographic and clinical data.

Participants underwent PET examination and cognitive testing on different days, with a mean of 5.9 days (SD 5.1) between examinations. At the time of cognitive testing, two FEP had been prescribed first-generation antipsychotics, with 3 and 6 days of total exposure respectively.

PET data on the participants of the present study is partly overlapping with a multimodal imaging study where PET and the high-affinity radioligand [11C]FLB 457, as well as diffusion-weighted imaging, was used to examine group differences in thalamic D2-R and connectivity, the results of which will be reported elsewhere.

Cognitive tests

Cognitive function was assessed using the MCCB as well as the Wisconsin Card Sorting Test (WCST). The MCCB was developed specifically to study cognitive domains known to be affected in schizophrenia and evaluates speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, and social cognition (See Supplementary Table 2 for a detailed description of the cognitive tests that make up each domain). WCST is a measure of executive function, specifically set-shifting. All FEP completed the MCCB, and all but two performed the WCST. All HC completed all cognitive tasks. The main outcome measures specified in the MCCB manual for the different cognitive domains were used, as well as percentage errors for the WCST.

A subgroup of FEP (N = 12, out of which 10 had a psychotic disorder) completed cognitive testing at 1.5-year follow-up (mean 590.92 days (SD = 66.07), see Supplementary Table 11 for additional information), using the same cognitive tests as described above. For this subgroup repeated measures of cognition were analyzed in the exploratory section. All other analyses involved measurements taken from two distinct samples described above; FEP and HC.

Image data acquisition and analysis

Structural MRI was obtained at Karolinska University Hospital, Solna, using a 3-T General Electric Discovery MR750 system (GE, Milwaukee, WI, USA).
T1-weighted images were used for the ROI delineation. Study participants were then examined at the Karolinska Institutet PET center, using a high-resolution research tomograph (Siemens Molecular Imaging, Knoxville, TN, USA). A transmission scan with a 137Cs source was performed prior to the emission scan to correct for attenuation. [11C]FLB 457 was prepared using in-target produced [11C] methane\(^{46}\) and injected as a rapid bolus into the antecubital vein. Mean injected radioactivity was 430.2 (SD 45.0) MBq; mean molar activity was 392.2 (SD 205.4) Gbq/micromole, and mean injected mass was 0.54 (SD 0.31) mg. All emission scans were 90 min long.

PET images were reconstructed into 3 × 1 min, 4 × 2 min, and 12 × 6 min subsequent frames using ordered subset expectation maximization. Head movement was further corrected by frame-to-frame realignment\(^{46}\). T1 images were co-registered to summation PET images using SPMS (Wellcome Trust Centre for Neuroimaging, London, UK) in Matlab 2014 (The Mathworks, Natick, MA, USA). All ROIs were then back-transformed using MRI-PET coregistration parameters and applied to the PET data. From this, regional time-activity curves were extracted and used in kinetic modeling.

Two FEP went out of the system during frame 14 and frames 7–9, respectively, owing to experiencing discomfort. For both individuals, a new transmission scan was then obtained for subsequent frames and the missing frames were excluded from the ensuing quantification.

The Logan Graphical Analysis\(^{46}\) with cerebellum as reference region was used to obtain BP\(_{ND}\) values for all ROIs. All quantification was performed using the “kinftr” package in R\(^{46}\).

**Analytic design and statistics**

Considering only a few previous studies have investigated D2-R in relation to cognitive function in FEP, we chose to examine our data in two ways; a confirmatory part and an exploratory part. This statistical study design was pre-registered and is publicly available at [https://aspredicted.org/cf82g.pdf](https://aspredicted.org/cf82g.pdf).

**Confirmatory analyses**

The confirmatory analyses were hypothesis-driven, examining associations between cognitive domains that are of particular importance in schizophrenia and brain regions thought to be involved in those cognitive processes. The cognitive domains chosen were verbal learning, working memory, and processing speed, as these domains have been identified as the most impaired in a meta-analysis of antipsychotic drug-naive FEP\(^{5}\). ROIs were DLPFC (for verbal learning, working memory, and speed of processing) as dysfunction in this region has been associated with schizophrenia pathology in general and with several forms of cognitive impairment;\(^{16,18}\) and the hippocampus (for verbal learning) given its specific importance in learning and memory for patients\(^{17}\).

First, we analyzed the relationship between D2-R availability and cognition in the whole sample. Thereafter, we repeated the analysis with an added interaction effect for FEP/HC status (as previous studies have pointed towards differential relationships between cognition and dopamine for FEP and HC, respectively (see Supplementary Table 1)). At last, we applied a Bayesian analysis in the confirmatory section, by calculating Bayes Factors, to quantify how much the data supports the alternative hypothesis over the null hypothesis and vice versa\(^{50}\).

**Age-correction of cognitive test scores**

Association between age and performance on cognitive tests is well-documented\(^{1}\), motivating the use of age-corrected cognitive test scores. Participants of this study were part of a larger cohort of FEP (N = 83) and HC (N = 59), who were tested with the same test battery. Inclusion and exclusion criteria were identical for this cohort as for the PET participants, with the exception that many FEP patients (N = 43) had been exposed to antipsychotic medication at the time of cognitive testing. For additional demographics, see Supplementary Tables 12, 13. As no Swedish norming of the MCCB exists, cognitive test scores were age-corrected using linear regression (raw cognitive test score = age) using the larger cohort of FEP and HC.

**Power analysis and correction for multiple comparisons**

We performed a power calculation using the lower bound of reported correlations from previous literature and the aim of being able to detect a correlation of moderate magnitude (considered to be an r = 0.5) in our sample. Cognitive results and BP\(_{ND}\) values in our selected ROIs were intercorrelated (cognitive tests \(r = 0.27–0.50\); ROIs \(r = 0.35\)), thus a Bonferroni correction for multiple comparisons was deemed too conservative. Instead, the alpha level was corrected by estimating the effective number of tests (Meff), an analytical approach using the correlations among the variables being tested while maintaining a consistent total family-wise error rate of 5%\(^{51}\). The ensuing significance threshold for the confirmatory tests was set to 0.027.

**Linear regression models**

From the power analysis, based on the corrected alpha, fixed sample size, and a beta of 0.2, we chose to perform four confirmatory linear regression models with [11C]FLB 457 BP\(_{ND}\) in ROIs as the dependent variable and (age-corrected) cognitive test scores as the independent variable. FEP/HC status and age were added as covariates. The following two-sided hypotheses were tested:

1. Verbal learning is correlated with D2-R BP\(_{ND}\) in the DLPFC.
2. Verbal learning is correlated with D2-R BP\(_{ND}\) in the hippocampus.
3. Working memory is correlated with D2-R BP\(_{ND}\) in the DLPFC.
4. Speed of processing is correlated with D2-R BP\(_{ND}\) in the DLPFC.

The significance threshold was kept on the same level for a secondary regression step, adding an interaction term for FEP/HC status, meaning that a marginally elevated overall alpha level was accepted. Pearson partial correlations were also calculated for the regression models.

For the Bayesian analysis, the null hypothesis (H0: there is no association between BP\(_{ND}\) and cognitive test scores) was defined so that the beta-coefficient denoting the BP\(_{ND}\)-cognition relationship was equal to zero. The alternative hypothesis (H1: there is an association between BP\(_{ND}\) and cognitive test scores) was defined so that the beta-coefficient was distributed according to a normal distribution, centered around zero with an SD of 0.5, meaning that BP\(_{ND}\) and cognitive test scores are related in some way, and gives higher prior plausibility to smaller relationships relative to larger relationships.

**Exploratory analyses**

The exploratory section utilized additional extrastriatal ROIs (thalamus, ACC, and TC) and cognitive domains (attention, visual learning, executive function, and neurocognitive composite) to investigate any potential relationship between cognition and D2-R. Associations were investigated using linear regression, with and without interaction effect, as well as Pearson partial correlation. Results were not corrected for multiple comparisons and should be viewed as hypothesis-generating and not hypothesis testing. For this reason, p values are solely reported as a continuous measure of indirect evidence against the null hypothesis\(^{52}\) and not interpreted in a dichotomous manner. Furthermore, potential relationships between D2-R levels at baseline and cognitive performance at 1.5-year follow-up, (as well as the relationship between D2-R levels at baseline and change in the level of cognitive function from baseline to follow-up) were explored for the cognitive tests and brain regions mentioned above.

All statistical analyses were performed using the statistical software R version 3.6.2\(^{24}\).

**Reporting summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**DATA AVAILABILITY**

Owing to institutional restrictions, the data cannot be shared openly but can instead be made available upon request on a case-by-case basis as allowed by the legislation and ethical pernits. Requests for access can be made to the Karolinska Institutet's Research Data Office at rdo@ki.se.

**CODE AVAILABILITY**

The code for reproducing the analyses and figures in this article can be found at [https://github.com/MariaLeeT/D2_cognition_FEP](https://github.com/MariaLeeT/D2_cognition_FEP).
REFERENCES

1. Aas, M. et al. A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation. Front. Psychiatry https://doi.org/10.3389/fpsyt.2013.00182 (2014).

2. Bowie, C. R. & Harvey, P. D. Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr. Clin. North Am. 28, 613–33 (2005).

3. Heinrichs, R. W. & Zakaria, K. K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychopharmacol. 12, 426–445 (1998).

4. Schaefer, J., Giangrande, E., Weinberger, D. R. & Dickinson, D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr. Res. 150, 42–50 (2013).

5. Fatouros-Bergman, H., Cervenka, S., Flyckt, L., Edman, G. & Farde, L. Meta-analysis of cognitive performance in drug-naive patients with schizophrenia. Schizophr. Res. 158, 156–62 (2014).

6. Kesby, J. P., Eyles, D. W., McGrath, J. J. & Scott, J. G. Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl. Psychiatry 8, 30 (2018).

7. Green, M. F. Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. J. Clin. Psychiatry 77, 8–11 (2016).

8. Howes, O. D. et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch. Gen. Psychiatry 69, 776–86 (2012).

9. Farde, L., Wiesel, F. A., Halldin, C. & Sedvall, G. Central D2-dopamine receptor binding in the anterior cingulate cortex and executive functioning. J. Int. Neuropsychol. Soc. 14, 110–118 (2008).

10. Nordstrom, A.-L. Central D2 dopamine receptor occupancy in relation to anti-psychotic drug effects. Biol. Psychiatry 33, 227–235 (1993).

11. Rigpe, S. et al. Biological insights from 180 schizophrenia-associated genetic loci. Nature 511, 421–427 (2014).

12. Volkow, N. D. et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am. J. Psychiatry 155, 344–349 (1998).

13. Bäckman, L. et al. Age-related cognitive deficits mediated by changes in the striatal dopamine system. Am. J. Psychiatry 157, 635–637 (2000).

14. Cervenka, S., Bäckman, L., Csélenyi, Z., Halldin, C. & Farde, L. Associations between dopamine D2 receptor binding and cognitive performance: a functional compartmentalization of the human striatum. Neuroimage 40, 1287–1295 (2008).

15. Veselínovíc, T. et al. The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophrenia. Psychopharmacology 235, 2221–2232 (2018).

16. Parkin, S. G. et al. Working memory and DLPCF inefficiency in schizophrenia: the FBRIN study. Schizophr. Bull. 35, 19–31 (2009).

17. Ragland, J. D. et al. Prefrontal activation deficits during episodic memory in schizophrenia joh. Am. J. Psychiatry 166, 863–874 (2009).

18. Francis, M. M. et al. Functional neuroanatomical correlations of episodic memory impairment in early phase psychosis. Brain Imaging Behav. 10, 1–11 (2016).

19. Fagerlund, B. et al. Relationship of frontal D2/3 binding potentials to cognition: a study of antipsychotic-naïve schizophrenia patients. Int. J. Neuropsychopharmacol. 16, 23–36 (2013).

20. Slifstein, M. et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 72, 316–24 (2015).

21. Vyas, N. S. et al. D2/D3 dopamine receptor binding with [F-18]fallypride correlates of executive function in medication-naïve patients with schizophrenia. Schizophr. Res. 192, 442–56 (2018).

22. Rao, N. et al. Impaired prefrontal cortical dopamine release in schizophrenia during a cognitive task: a [11C]CFLB 457 positron emission tomography study. Schizophr. Bull. 45, 670–79 (2018).

23. Lummé, V., Aalto, S., Ilonen, T., Nägren, K. & Hietala, J. Dopamine D2/D3 receptor binding in the anterior cingulate cortex and executive functioning. Psychiatry Res. 156, 69–74 (2007).

24. Lummé, V. et al. Cortical dopamine D2/D3 receptors and verbal memory in man. Neuroimage 51, 918–922 (2010).

25. Takahashi, H. et al. Memory and frontal lobe functions; possible relations with dopamine D2 receptors in the hippocampus. Neuroimage 34, 1643–1649 (2007).

26. Takahashi, H. et al. Behavioral/systems/cognitive differential contributions of prefrontal and hippocampal dopamine D 1 and D 2 receptors in human cognitive functions. J. Neurosci. 28, 12032–038 (2008).

27. Lee, M. D. & Wagenmakers, E.-J. Bayesian cognitive modeling: a practical course. (Cambridge University Press, 2013).

28. Kern, R. S. et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am. J. Psychiatry 165, 214–20 (2008).

29. Mohn, C., Sundet, K. & Rund, B. R. The Norwegian standardization of the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery. J. Clin. Exp. Neuropsychol. 34, 667–677 (2012).

30. Lezak, M. D., Howieson, D. B., Bigler, E. D. & Tranel, D. Neuropsychological Assessment. (Oxford University Press, 2012).

31. Matheson, G. J. et al. Clinical brain PET research must embrace multi-centre collaboration and data sharing or risk its demise. Eur. J. Nucl. Med. Imaging 47, 502–504 (2020).

32. Nuechterlein, K. H. et al. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 165, 203–13 (2008).

33. Grant, B. Y. D. & Berg, E. A. A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a weight-type card-sorting problem. J. Exp. Psychol. 38, 404–411 (1988).

34. Andersson, J., Truong, P. & Hallidin, C. In-target produced [11C]methane: Increased specific radioactivity. Appl. Radiat. Isot. 67, 106–110 (2009).

35. Schain, M. et al. Quantification of serotonin transporter availability with [11C]MADAM - a comparison between the ECAT HRRT and HR systems. Neuroimage 60, 800–807 (2012).

36. Logan, J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl. Med. Biol. 27, 661–670 (2000).

37. Tjerkaski, J., Cervenka, S., Farde, L. & Matheson, G. J. Kinfir – an open source tool for reproducible PET modelling: validation and evaluation of test-retest reliability. Brain https://doi.org/10.1093/brain/awz078 (2020).

38. Wagenmakers, E. J., Morey, R. D. & Lee, M. D. Bayesian benefits for the pragmatic researcher. Curr. Dir. Psychol. Sci. 25, 169–176 (2016).

39. Dieringer, J., University of I. A simple correction for non independent tests. Psy-Ariv 15, 7577–7578 (2018).

40. Perezgonzalez, J. D. Fisher, Neyman-Pearson or NHST? A tutorial for teaching data testing. Front. Psychol. 6, 1–11 (2015).

41. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria (2020).

ACKNOWLEDGEMENTS

We wish to thank the volunteers with FEP and the HC subjects without whom this study had not been possible. We also thank research nurses Joachim Eckerström, Marie Adolfsdotter, Georgia Juntura, Martin Stålebäck, Henrik Grognesvoll; the staff at Psykiatri Nordväst, Norra Stockholms Psykiatri, PRMA Vuxensykevård, Psykiatri Södra; and the staff of the PET group at Karolinska Institutet for their invaluable assistance during this study. The study was supported by the Swedish Research Council (Grant no. 523-2014-3467 (S.C.), 2017-00875 (S.E.), 09114 (L.F.), Karolinska Institutet and Stockholm County Council
S.C., L.F., S.E., C.M.S.) and Torsten Söderberg Stiftelse (S.E.). P.P.S. was supported by the Swedish Society for Medical Research and the Lundbeck Foundation.

**AUTHOR CONTRIBUTIONS**

S.C., L.F., H.F.B., P.P.S and M.L designed the study. P.I.V., H.F.B. and M.L. collected the data. M.L. and P.P.S. carried out the statistical analyses. S.C. and M.L. drafted the manuscript. All authors critically revised the article and approved the final version for publication.

**FUNDING**

Open access funding provided by Karolinska Institute.

**COMPETING INTERESTS**

S.C. has served as a one-off speaker for Otsuka Pharmaceuticals. L.F. was at the time of data collection partially employed at the AstraZeneca PET imaging Centre at Karolinska Institutet. C.M.S. is a scientific advisor to Outermost Therapeutics Inc. The remaining authors declare no competing interests.

**ADDITIONAL INFORMATION**

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41537-021-00176-x.

**Correspondence** and requests for materials should be addressed to Maria Lee.

**Reprints and permission information** is available at http://www.nature.com/reprints

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

© The Author(s) 2021